EsoCap AG announced presentation of new data, with smart application technology in the upper gastrointestinal tract demonstrating that long-lasting topical drug therapy within the esophagus is achievable for the first time. The University of Greifswald, Germany, conducted an imaging study in twelve healthy volunteers, with the objective of evaluating esophageal disposition of thin films. The […]
The Scientific Platform
The EsoCap drug delivery platform will represent a CHANGE IN PARADIGM, similar as it happened with aerosol therapy in asthma.
Addressing Major Medical Needs
EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.
EsoCap AG is led by one of the most experienced teams in the industry.
Our team has founded, led and grown some of the most important companies impacting patients’ lives through the development and the commercialization of major life-transforming medicines.
EsoCap AG has received Orphan Drug Designation from the United States Food & Drug Administration (FDA) for use of ESO-101 in the treatment of EoE (eosinophilic esophagitis). “We are pleased that the FDA has recognized ESO-101’s potential to offer a significant therapeutic benefit for patients suffering from EoE”, said Isabelle Racamier, EsoCap AG CEO, “We […]
EsoCap AG organized a multidisciplinary scientific advisory board meeting in Zurich with thirteen international experts on June 27, 2019. As an introduction, Prof. Werner Weitschies, Center for Drug Absorption and Transport at the University of Greifswald, gave a presentation on the Esophageal Wafer Study conducted in healthy volunteers by the University of Greifswald. The excellent […]
EsoCap AG announced that a capital increase has been authorized by the Extraordinary General Assembly, held on April 11, 2019, followed by successful completion of a private placement financing. The proceeds of the private placement will be used to complete a clinical proof-of-concept trial in eosinophilic esophagitis (EoE). “We are delighted to have secured the […]
EsoCap AG is one of just a handful of companies in the area of biotech and medtech selected to present at the Bio-Europe conference start-up spotlight on March 26th, 2019 in Vienna.
Basel, Switzerland, February 6, 2019 EsoCap AG and LTS Lohmann Therapy-Systeme AG announced the start of cooperation on industrial development of a unique drug delivery technology for diseases of the upper gastrointestinal tract. This collaboration leverages the collective expertise of a strong partner in the thin film industry with a highly innovative application technology. “We […]
Basel, Switzerland, July 13th, 2018 EsoCap AG announced that it has successfully completed a private placement financing round on July 13th, 2018. The proceeds of the capital increase will be used toward the completion of the technical development of EsoCap’s unique drug delivery technology and the initiation of a clinical proof-of-concept trial in eosinophilic esophagitis […]
EsoCap AG organized a scientific advisory board meeting with eight international experts in Eosinophilic Esophagitis (EoE) in Zürich on June 14th, 2018.
Prof. Dr. Werner Weitschies, Head of the Center of Drug Absorption and Transport at the University of Greifswald gave a keynote presentation on EsoCap’s unique drug delivery platform.
EsoCap AG announced today that the South Africa Patent and Trademark Office has issued the Patent No. 2017/03831 on March 28th, 2018 which is directed at the smart application technology enabling specific site-directed treatments of several diseases of the esophagus.
EsoCap announced that Sven Hoffmann and Isabelle Racamier have been appointed to the Company’s Board of Directors. “I am delighted to welcome Isabelle and Sven to the EsoCap Board. Both of them are highly talented executives bringing deep industry experience and a proven track record of building value” said Dr. Werner Tschollar, Chairman of the […]
EsoCap AG and the University of Greifswald in Germany announced that they have entered into a licensing agreement granting EsoCap the exclusive worldwide rights for the unique drug delivery technology developed by the University of Greifswald. Prof. Werner Weitschies, Head of the Center of Drug Absorption and Transport and his team at the University of […]
EsoCap AG is located in Basel, a major center for innovation.
2017 © EsoCap AG | Malzgasse 9
Welcome to EsoCap AG. By using our website, you are accepting the following:
Copyright and Limitation of Liability
This website and its content are copyrighted by EsoCap AG. You may use, e.g. download or copy any content from this website for personal use only. Any other use of the content of this website is not permitted.
This website is for information purposes only and does not contain medical advice. While we are diligently updating our website, we are not bound by the information published and do not guarantee the content to be accurate or up-to-date. EsoCap AG cannot be held liable for any damage that could arise out of or in connection with the use of this website. EsoCap AG is particularly not responsible for damage resulting from incorrect, incomplete or outdated information or the loss of data. In case we are linking to other websites, EsoCap AG is not responsible for such third-party websites. All such limitations are subject to the extent permissible under the applicable law.
Privacy and Personal Data
EsoCap AG respects your privacy. You can browse this website without providing us with personal data. We may collect, store and process your personal data if you contact us by email. We may use your personal data for administrative purposes and to inform you about our services and products. We will not provide third parties with your personal data for purposes other than those listed.